Radiopharmaceutical · Acts on integrin alphaVbeta6 (ITGB6) · developed by Radiopharm Theranostics
Gallium Ga 68 relitegatide brexetan is a PET radiotracer made of an integrin alphaVbeta6-binding peptide labeled with gallium Ga 68. The peptide binds integrin alphaVbeta6-expressing cancer cells, allowing their visualization by positron emission tomography. It is studied in pancreatic, lung, esophageal, cervical, endometrial and ovarian cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05799274 | Phase 1 | Healthy Volunteers | Active not recruiting | RADX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cervical CancerEndometrial CancerEsophageal Squamous Cell CarcinomaHealthy VolunteersNon-small Cell Lung Cancer (NSCLC)Ovarian CancerPancreatic Ductal Adenocarcinoma
Updated Oct 25, 2026. Something wrong or missing? Report it on the RADX page.
See RADX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RADX catalysts and pipeline →